Kim, B.K.; Cheon, J.; Kim, H.; Kang, B.; Ha, Y.; Kim, D.Y.; Hwang, S.G.; Chon, Y.E.; Chon, H.J.
Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. Cancers 2022, 14, 1747.
https://doi.org/10.3390/cancers14071747
AMA Style
Kim BK, Cheon J, Kim H, Kang B, Ha Y, Kim DY, Hwang SG, Chon YE, Chon HJ.
Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. Cancers. 2022; 14(7):1747.
https://doi.org/10.3390/cancers14071747
Chicago/Turabian Style
Kim, Beom Kyung, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do Young Kim, Seong Gyu Hwang, Young Eun Chon, and Hong Jae Chon.
2022. "Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study" Cancers 14, no. 7: 1747.
https://doi.org/10.3390/cancers14071747
APA Style
Kim, B. K., Cheon, J., Kim, H., Kang, B., Ha, Y., Kim, D. Y., Hwang, S. G., Chon, Y. E., & Chon, H. J.
(2022). Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. Cancers, 14(7), 1747.
https://doi.org/10.3390/cancers14071747